{"url_path":"/sec/txmd/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other information**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/25743/0001213900-26-055081-index.html","accession_number":"0001213900-26-055081","cik":"0000025743","ticker":"TXMD","issuer_name":"TherapeuticsMD, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/25743/0001213900-26-055081-index.html","primary_entity_key":"0000025743","primary_entity_name":"TherapeuticsMD, Inc."},"word_count":46,"has_tables":true,"body_markdown":"**Item 5. Other information**\n\n \n\n**Rule 10b5-1 Trading Plans**\n\n \n\nDuring the three months ended March 31, 2026, none of our directors\nor officers adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined\nin Item 408 of Regulation S-K)."}